Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

3.0K
The pathophysiology of pneumonia involves the following steps:
3.0K
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

3.6K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
3.6K
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

980
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
980
Pathophysiology of Vomiting01:22

Pathophysiology of Vomiting

3.1K
Vomiting is a complex physiological response to expel harmful or irritating substances from the body. It's a defensive mechanism triggered by stimuli like poisons, microbial toxins, cytotoxic drugs, and mechanical abdominal distension. The process is centrally coordinated by the vomiting (or emetic) center located in the medulla of the brainstem. This area, rich in muscarinic M1, histamine H1, neurokinin 1 (NK1), and serotonin 5-HT3 receptors, coordinates the act of vomiting through...
3.1K
Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

1.3K
Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
1.3K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

978
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
978

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ascophyllan Supplementation Is Safe and Associated with Exploratory Modulation of Innate Immune Phenotypes, Biochemical Parameters, and the Gut Microbiome in a Randomized Pilot Trial.

Marine drugs·2026
Same author

Nintedanib inhibits the VEGFR-ERK signaling pathway in human KRAS-mutated cancer cells.

Cell death & disease·2026
Same author

Awareness and Utilization of the Revised Second International Staging System (R2-ISS) and 1q21 Gain/Amplification Testing: A Nationwide Web-Based Survey of Hematologists in Japan.

Cancer medicine·2026
Same author

Vaccine-Induced Anti-HBs Response is Associated with Protection Against Hepatitis B Virus Reactivation after Allogeneic Hematopoietic Cell Transplantation: A Randomized Trial.

Transplantation and cellular therapy·2026
Same author

Guidelines and consensus for minimal residual disease-adapted therapy in multiple myeloma from the Pan-Pacific multiple myeloma working group.

Clinical hematology international·2026
Same author

Neuroblastoma cell growth and survival promoted by DNMT3B and its inhibition demonstrates anti-tumor effects.

Pediatric research·2026

Related Experiment Video

Updated: Feb 9, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

9.1K

[Multiple myeloma: update on pathophysiology and management].

Ichiro Hanamura1, Shinsuke Iida2

  • 1Department of Internal Medicine, Division of Hematology, Aichi Medical University School of Medicine.

[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology
|June 8, 2018
PubMed
Summary

Recent advances in multiple myeloma (MM) treatments, including new drugs and CAR T-cell therapies, show promise for personalized medicine and cures. Next-generation sequencing studies are revealing MM

Keywords:
CAR-TIntraclonal heterogeneityMonoclonal antibodyMyeloma

More Related Videos

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma
07:53

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Published on: April 15, 2022

4.8K
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.5K

Related Experiment Videos

Last Updated: Feb 9, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

9.1K
Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma
07:53

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Published on: April 15, 2022

4.8K
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.5K

Area of Science:

  • Hematology
  • Oncology
  • Genomics

Background:

  • Multiple myeloma (MM) treatment has significantly improved since 2000 with proteasome inhibitors and immunomodulatory drugs.
  • Monoclonal antibodies like daratumumab and elotuzumab, approved in 2015, target relapsed/refractory MM (RRMM).
  • Emerging therapies include venetoclax (BCL-2 inhibitor) and BCMA-targeted CAR T-cell therapy, showing high efficacy in early studies.

Purpose of the Study:

  • To review the genomic landscape of MM based on next-generation sequencing (NGS) studies.
  • To discuss recent therapeutic advancements in MM treatment.
  • To highlight the potential of personalized medicine and curative strategies for MM.

Main Methods:

  • Review of current knowledge on MM genomics from NGS studies.
  • Analysis of recent therapeutic progress in MM.
  • Discussion of specific agents: elotuzumab, daratumumab, ixazomib, venetoclax, and BCMA CAR-T therapies.

Main Results:

  • NGS studies have elucidated the molecular complexity and heterogeneity of MM.
  • Venetoclax shows efficacy in RRMM with specific genetic markers (t(11;14), high BCL-2/BCL-XL).
  • BCMA CAR-T therapies induce significant remissions in highly refractory MM cases.

Conclusions:

  • Personalized medicine and curative approaches for MM are becoming increasingly feasible.
  • Understanding MM genomics through NGS is crucial for developing targeted therapies.
  • The combination of novel agents and advanced therapies offers new hope for MM patients.